PHG Needs Assessment Calculator Romania Preconception Care and Screening

Welcome to the PHG Health Needs Assessment Calculator for Preconception Care and Screening. The contents of this file are listed below.

Full name of the sheet	Short name
Country demographic, maternal health and socioeconomic indicators	Demography
Country health-service data	HealthServices
Risk factors for congenital disorders in women of reproductive age	PCCS-NA1.1
Population prevalence and variation for genetic conditions	PCCS-NA1.2
Effect of folic acid fortification on birth incidence of congenital heart disease	PCCS-CHD
Effect of maternal age on birth incidence of Down's syndrome	PNS-DOWNS
Effect of preconception care on fetal alcohol spectrum disorders	PCCS-FASD
Effect of preconception folic acid fortification and supplementation on neural tube defects	PCCS-NTD
Effect of preconception care on incidence of orofacial clefts	PNS-OFC
Effect of immunisation on rubella incidence in women	PNS-RUB
Effect of preconception screening and treatment on incidence of syphilis	PNS-SYPH
Effect of preconception care on congenital disorders caused by teratogens	PNS-TER

Shared Data

Demographic, maternal health and socio-economic indicators

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Demography information from that Calculator into here. The information should be the same.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Number of persons by age-group and sex	Estir	nates		Yo	ur estimat	es	Cho	sen estim	ates
Age group	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4 years	558232	528013	1086245			0			0
5-9 years	544950	515289	1060239			0			0
10-14 years	566271	539363	1105634			0			0
15-19 years	646396	617312	1263708			0			0
20-24 years	880085	845711	1725796			0			0
25-29 years	830994	792972	1623966			0			0
30-34 years	908512	861023	1769535			0			0
35-39 years	850839	821235	1672074			0			0
40-44 years	844271	832093	1676364			0			0
45-49 years	613462	624305	1237767			0			0
50-54 years	728226	776890	1505116			0			0
55-59 years	671502	749830	1421332			0			0
60-64 years	509384	598618	1108002			0			0
65+ years	1297969	1908439	3206408			0			0
Total	0	0	21462186	0	0	0	0	0	0
Female population aged 15-44 years		0			-			-	
Data year	in 2011								
Source, Year	UN 2011								

Ethnicity. Please enter data for the main ethnic groups if you are working with a population that is different from that of the country.

Ethnic group	Number	% population

Fertility and mortality	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Crude birth rate: live births (LB) / year / 1000 population	10	Unicef,				
Still birth rate (SB): Still births (SB) / year / 1000 total births	4	WHO, 2009				
Total births in 1000s (LB+SB) per year	211	Unicef,				
Infant mortality rate: infant deaths / 1000 LB / year	11	UNICEF				
Under-5 mortality rate: U5 deaths / 1000 LB / year	14	UNICEF				
Percentage births in women >35 years						
Life expectancy at birth (yrs)	73	WHO, 2009				
% of marriages consanguineous						

Maternal health	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Prenatal visits – at least 1 visit (%)	94	WHO, 2004				
Prenatal visits – at least 4 visits (%)	76	WHO, 2004				
Births attended by skilled health personnel (%)	98.7	WHO, 2008				
Contraception prevalence rate (%)	70.3	WHO, 2004				
Unmet need for family planning (%)	11.9	WHO, 2004				
Total fertility rate	1.3	WHO, 2009				
% home births						
% births at health care services						
Newborn health	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Number of neonatal examinations by SBA / trained staff						
% neonatal examinations by SBA / trained staff						

Socio-economic indicators	Estimate	Year	Your	Source,	Chosen	Source,
Gross national income per capita (PPP int. \$)	13380	WHO, 2008				
% population living on < US\$1 per day	<2.0	WHO, 2005				
Birth registration coverage (%)	>90	WHO, 2008				
Death registration coverage (%)	90-100	WHO, 2009				

LB = live births

PPP = purchasing power parity

SBA = skilled birth attendant

Romania Shared Data Health services data

Please read first! If you have already completed a needs assessment for a different topic in this country, you will be able to copy the Health Services information from that Calculator into here. The information should be the same.

This section provides health-service-related information for your country.

By default, the Toolkit contains information at the national level.

If you would like to use a different population, then replace country information with that of your specific population of interest.

Health Evpanditure	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Health Expenditure			estimate	Tear	estimate	Tear
Per capita total expenditure on health (PPP int. \$)	773	WHO, 2009				
Total expenditure on health as percentage of GDP	5.4	WHO, 2009				
Per capita government expenditure on health (PPP int. \$)	610	WHO, 2009				
External resources for health as percentage of total expenditure on health	0	WHO, 2009				
General government expenditure on health as percentage of total expenditure on health	78.9	WHO, 2009				
Out-of-pocket expenditure as percentage of private expenditure on health	98.1	WHO, 2009				
Private expenditure on health as percentage of total expenditure on health	17.4	WHO, 2009				
General government expenditure on health as percentage of total government expenditure	11.8	WHO, 2009				

		Source,	Your	Source,	Chosen	Source,
Health Workforce	Estimate	Year	estimate	Year	estimate	Year
Number of nursing and midwifery personnel	90698	WHO, 2006				
Nursing and midwifery personnel density (per 10,000		WHO, 2006				
population)	41.9					
Number of physicians	41455	WHO, 2006				
Physician density (per 10 000 population)	19.166	WHO, 2006				
Number of obstetricians						
Number of paediatricians						
Number of paediatric surgeons						
Number of paediatric cardiac surgeons						

Number of paediatric neurosurgeons			
Number of clinical geneticists			

Number of genetic counsellors			
Number of community health workers			
Number of skilled birth attendants (SBA)			
Density of SBA			
Number of lab staff providing cytogenetic testing			
Number of lab staff providing molerating aggestic for			
genetics			
Number of skilled health attendants			

Infrastructure	Estimate	Source, Year	Your estimate	Source, Year	Chosen estimate	Source, Year
Number of maternity units	Louinate	l cai	Communic	loai	Commute	leai
Number of services providing specialised care for people with CD						
Number of family planning services						
Number of preconception services						
Number of services providing prenatal care						
Number of services providing newborn care						
Number of facilities providing genetic services						
Number of laboratories providing cytogenetics						
Number of laboratories providing molecular genetics						
Number of laboratories providing biochemical tests for genetics						
Number of facilities for safe terminations of pregnancies for fetal defects						

PPP = purchasing power parity GDP = gross domestic product SBA = skilled birth attendant CD = congenital disorders

Preconception care and screening

Risk factors for congenital disorders in women of reproductive age

Risk factors	Proportion of women with risk factor	Qualitative assessment*	Variation	Source
Obesity				
Diabetes				
Malnutrition				
Teratogen exposure: environmental, agricultural and				
PSPUSATION Terratogenic prescribed and non-prescribed				
gyphiniges				
Rubella susceptibility				
Rubella infection				
Other infections (e.g. CMV or HIV)				
Alcohol consumption				
Tobacco use				
Advanced maternal age (>35)				
lodine deficiency				
Folate deficiency				
Other risk factors				

^{*} Complete if numerical data are unavailable. Use numbers from 1 to 5, where 1 = low importance and 5 = high importance.

Romania
Preconception care and screening
Population prevalence and variation for genetic conditions

Condition	Prevalence per 1000 TB	Prevalence variation and high-risk populations	Tick if PCCS available	Type of PCCS available
Thalassaemias				
Sickle cell disease				
Rhesus incompatability				
G6PD deficiency				
Cystic fibrosis				
Other				

TB = total births (live births + still births)
PCCS = PreconCeption Care and Screening

Preconception care and screening

Effect of folic acid fortification* on birth incidence of congenital heart disease

This sheet allows you to estimate the potential reduction in CHD prevalence through fortification of food with folic acid.

Please start by entering values reflecting your current situation. If you have no fortification programme, enter 0 for coverage.

Below, you may adjust dosage and coverage levels to demonstrate the effects of different intervention scenarios.

Current situation	Notes
Present estimated CHD prevalence per 1000 TB	
Present dosage (ppm)	Range: 1.5 to 3
Present coverage of fortification	Range: 0 to 1
Baseline CHD prevalence per 1000 TB, with no folic acid fortification*1	

Potential scenarios, based on your present situation		
Vary dosage (ppm)		Range: 1.5 to 3
Vary proportional population coverage		Range: 0 to 1
Estimated reduction in CHDs through folic acid fortification, per 1000 TB ²	0.000	Do not delete this value!
Resulting prevalence of CHDs after folic acid fortification, per 1000 TB ³	0.000	Do not delete this value!

ppm = parts per million

TB = total births (live births + still births)

The regression formula underlying the effect on neural tube defects is given in the NTD Calculator in this Toolkit.

^{*} The effect of folic acid on CHD is assumed to be 25% of the effect on neural tube defects.

^{**} Not considering the effects of other interventions on prevalence.

¹(Present estimated prevalence-(1.07*coverage*0.25)+(0.15*ppm*coverage*0.25))/(1-0.88*coverage*0.25)))

²((0.25*(Baseline CHD-(1.07*coverage+0.12*baseline CHD*coverage-0.15*dosage*coverage+baseline-baseline*coverage))))

³Baseline CHD prevalence – estimated reduction in CHD after fortification

Effects of folic acid supplementation on CHD

Effect of supplementation (with no fortification)	Notes
Baseline prevalence with no folic acid intervention (per 1000 TB)	This can be taken from the appropriate cell above
Maximum proportional reduction (assuming 100% coverage)	0.18 This value is fixed at 0.18
Population supplementation coverage	Range: 0 to 1
Actual proportional reduction	0 Maximum proportional reduction x Coverage
Actual prevalence reduction (per 1000 TB)	0.000 Baseline prevalence x Actual proportional reduction

	Baseline prevalence -((Maximum prop. Reduction x Population supplementation coverage) x Baseline
New prevalence	0.000 prevalence))
% prevalence reduction	#DIV/0! 1-(New prevalence/Baseline prevalence)
Absolute prevalence reduction (per 1000 TB)	0.000 Baseline prevalence -New prevalence

Now you can see below the potential combined effect of folate fortification and supplementation:

Additional effect of supplementation, given fortification	0.1	I his value can be changed.
	New prevalence	
After fortification		This can be taken from the appropriate cell above
After supplementation	0.000	Same as new prevalence
		Prevalence after fortification-(Additional effect of
		supplementation*prevalence after
After fortification and supplementation		supplementation)

TB = total births (live births + still births)

CHD = congenital heart disease

Preconception care and screening

Effects of maternal age on incidence of Down's syndrome

If you have an estimate for the birth prevalence of Down's syndrome, you can use the Calculator on the left.

If you have an estimate of the proportion of births that are to mothers aged over 35, you can use the Calculator on the right.

Birth prevalence per 1000 TB		
Proportional birth prevalence due to high maternal age ¹	#DIV/0!	
Birth prevalence attributable to high maternal age, per 1000 TB ²	-0.86	
Baseline prevalence without maternal age effect	0.86	This figure is set at 0.86

Proportion of mothers aged >35		Range: 0 to 1
Estimated birth prevalence per 1000 TB³	0.86	
Proportional birth prevalence due to high maternal age ⁴	0.00	
Birth prevalence attributable to high maternal age, per 1000 TB⁵	0	
Baseline prevalence without maternal age effect		This figure is set at 0.86

TB = total births (live births + still births)

¹(Birth prevalence – 0.86)/Birth prevalence

²Birth prevalence – Baseline prevalence

³0.86+(7*Proportion of mothers aged >35)

⁴(Estimated birth prevalence- Baseline prevalence)/Estimated birth prevalence

⁵Estimated birth prevalence*Proportional birth prevalence

Preconception care and screening

Effect of preconception care on fetal alcohol spectrum disorders

Baseline prevalence of FASD per 1000 total births (live + still)		
Baseline prevalence of unsafe alcohol consumption in women aged 15-44 per 1000		
Variables		
Proportion of women reducing alcohol consumption to safe levels before conception		Range: 0 to 1
Effectiveness of preconception intervention on the outcome		Range: 0 to 1
Results		
% prevalence reduction due to preconception intervention per 1000 total births ¹	0%	
Final prevalence of unsafe alcohol consumption in women aged 15-44 per 1000 ²	0.00	
Final prevalence of FASD per 1000 births ³	0.00	

FASD = fetal alcohol spectrum disorder

¹Prop. Women reducing alcohol consumption x Effectiveness of intervention

²Baseline prevalence of unsafe alcohol consumption - (% prevalence reduction due to intervention X baseline prevalence of unsafe alcohol consumption)

³Baseline prevalence of FASD - (% prevalence reduction due to preconception intervention X Baseline prevalence of FASD)

Preconception care and screening

Effect of preconception folic acid fortification and supplementation on neural tube defects

This sheet allows you to estimate the potential reduction in NTD prevalence through fortification of food with folic acid and supplementation. Please start by entering values reflecting your current situation. If you have no fortification programme, enter 0 for coverage. Below, you may adjust dosage and coverage levels to demonstrate the effects of different intervention scenarios.

Current situation		Notes
Present estimated NTD prevalence per 1000 TB		
Present dosage (ppm)		Range: 1.5 to 3
Present coverage of fortification		Range: 0 to 1
Baseline NTD prevalence per 1000 TB, with no folic acid fortification*1		
Minimum prevalence NTD / 1000 births	0.9	This value is fixed at 0.9

Potential scenarios, based on your present situation		
Vary dosage (ppm)		Range: 1.5 to 3
Vary proportional population coverage		Range: 0 to 1
Estimated NTD prevalence with this scenario, per 1000 TB ²		<- Do not modify this cell!
Absolute prevalence reduction with this scenario, per 1000 TB ³		<- Do not modify this cell!

ppm = parts per million

TB = total births (live births + stillbirths)

 ${}^{1}IF(B10="";"";IF(((B10-(1.07*B12)+(0.15*B11*B12))/(1-0.88*B12)) < B15;B15;((B10-(1.07*B12)+(0.15*B11*B12))/(1-0.88*B12))) < B15;B15;((B10-(1.07*B12)+(0.15*B11*B12))/(1-0.88*B12)))}$

 $^2\ \mathsf{IF}(\mathsf{B}13="";"";\ \mathsf{IF}(\mathsf{B}13=0.9;0.9;\mathsf{IF}((1.07*\mathsf{B}19+0.12*\mathsf{B}13*\mathsf{B}19-0.15*(\mathsf{IF}(\mathsf{B}18="";\mathsf{B}11;\mathsf{B}18))*\mathsf{B}19+\mathsf{B}13-\mathsf{B}13*\mathsf{B}19)<\mathsf{B}15;\mathsf{B}15;(1.07*\mathsf{B}19+0.12*\mathsf{B}13*\mathsf{B}19-0.15*(\mathsf{IF}(\mathsf{B}18="";\mathsf{B}11;\mathsf{B}18))*\mathsf{B}19+\mathsf{B}13-\mathsf{B}13*\mathsf{B}19))))$

³IF(B20="";"";B13-B20)

See sheet NTD-Appx for explanation of regression.

^{*} Not considering the effects of other interventions on prevalence.

NTD Interventions 2: Effect of folic acid supplementation

This sheet allows you to estimate the potential reduction in NTD incidence through folic acid supplementation for pregnant women. Please enter a value for population coverage of folic acid supplementation, to determine its potential effect.

Effect of supplementation (with no fortification)	Notes	
Baseline prevalence with no folic acid intervention (per 1000 TB)		This can be taken from the appropriate cell (baseline NTD prevalence) in sheet NTD-Interv1.
Maximum proportional reduction (assuming 100% coverage)	0.72	This value is fixed at 0.72
Population supplementation coverage		Range: 0 to 1
Actual proportional reduction	0	Maximum proportional reduction x Coverage
Actual prevalence reduction (per 1000 TB)	0.000	Baseline incidence x Actual proportional reduction
Minimum prevalence	0.9	This value is fixed at 0.9
New prevalence		Baseline prevalence-((Maximum proportional reduction X Population supplementation coverage) x Baseline prevalence)
% prevalence reduction	#DIV/0!	1 – (New prevalence/Baseline prevalence)
Absolute prevalence reduction (per 1000 TB)	0.000	Baseline prevalence- New prevalence
Final prevalence following supplementation	0.900	Cannot go below 0.9 / 1000 LB

Now you can see below the potential combined effect of folate fortification and supplementation:

Additional effect of supplementation, given fortification	This value can be changed.		
	New preval	ence	
After fortification		This value set in sheet NTD-Interv1	
After supplementation			
After fortification and supplementation	0.000	Requires input in blank cells above ¹	
% reduction	#DIV/0!	Requires input in blank cells above ²	
Final prevalence after fortification and supplementation			

TB = total births (live births + stillbirths)

Otherwise use: (Baseline prevalence – new prevalence after fortification and supplementation)/baseline prevalence

¹New Prevalence after fortification-(Additional effect of supplementation x Final prev. following supplemen.)

²If New prevalence after fortification < minimum prevalence then use (Baseline prev – min prevalence)/baseline prevalence)

Preconception care and screening

Effect of preconception care on incidence of orofacial clefts

OFC Interventions 1: Effect of folic acid fortification*

This sheet allows you to estimate the potential reduction in OFC prevalence through fortification of food with folic acid. Please start by entering values reflecting your current situation. If you have no fortification programme, enter 0 for coverage. Below, you may adjust dosage and coverage levels to demonstrate the effects of different intervention scenarios.

Current situation	Notes
Present estimated OFC prevalence per 1000 TB	
Present dosage (ppm)	Range: 1.5 to 3
Present coverage of fortification Baseline OFC prevalence per 1000 TB, with no folic acid	Range: 0 to 1
fortification**	

Potential scenarios, based on your present situation		
Vary dosage (ppm)		Range: 1.5 to 3
Vary proportional population coverage		Range: 0 to 1
Estimated reduction in OFCs through folic acid fortification, per 1000 TB ²	0.000	Do not delete this value!
Resulting prevalence of OFCs after folic acid fortification, per 1000 TB	0.000	Do not delete this value!

ppm = parts per million

TB = total births (live births + still births)

The regression formula underlying the effect on neural tube defects is given in the NTD Calculator in this Toolkit.

^{*} The effect of folic acid on OFCs is assumed to be 25% of the effect on neural tube defects.

^{**} Not considering the effects of other interventions on prevalence.

¹(Present estimated prevalence-(1.07*coverage*0.25)+(0.15*ppm*coverage*0.25))/(1-0.88*coverage*0.25)))

²((0.25*(Baseline OFC-(1.07*coverage+0.12*baseline OFC*coverage-0.15*dosage*coverage+baseline-baseline*coverage))))

³Baseline OFC prevalence – estimated reduction in OFC after fortification

OFC Interventions 2: Effect of folic acid supplementation

Effect of supplementation (with no fortification)	Notes
Baseline prevalence with no folic acid intervention (per 1000 TB)	This can be taken from the appropriate cell above
Maximum proportional reduction (assuming 100% coverage)	0.18 This value is fixed at 0.18
Population supplementation coverage	Range: 0 to 1
Actual proportional reduction	0 Maximum proportional reduction x Coverage
Actual prevalence reduction (per 1000 TB)	0.000 Baseline incidence x Actual proportional reduction

New prevalence	Baseline prevalence with no intervention -((Maximum prop. 0.000 Reduction x Pop. Supp. Coverage) X Baseline prevalence)
% prevalence reduction	#DIV/0! 1-(New prevalence/Baseline prevalence)
Absolute prevalence reduction (per 1000 TB)	0.000 Baseline prevalence – New prevalence

Now you can see below the potential combined effect of folate fortification and supplementation:

Additional effect of supplementation, given fortification	This value can be changed.
	New prevalence This can be taken from the appropriate cell (resulting OFC
After fortification	This can be taken from the appropriate cell (resulting OFC
	prevalence)
After supplementation	0.000 Requires input in blank cells above
After fortification and supplementation ¹	Requires input in blank cells above

TB = total births (live births + still births)

OFC = orofacial clefts

¹Prevalence after fortification-(Additional effect of supplementation*prevalence after supplementation)

Preconception care and screening

Effect of immunisation on rubella incidence in women

Variables Coverage of rubella immunisation Proportion of women of reproductive age receiving immunisation Effectiveness of immunisation (proportion of cases prevented among those immunised) Results Prevalence reduction due to immunisation, per 1000 women aged 15-44² Range: 0 to 7 Ran			
Coverage of rubella immunisation Proportion of women of reproductive age receiving immunisation Effectiveness of immunisation (proportion of cases prevented among those immunised) Results % prevalence reduction due to immunisation, per 1000 women aged 15-44² Range: 0 to 7 Range: 0 to	Baseline prevalence of rubella in women aged 15-44 per 1000		
Proportion of women of reproductive age receiving immunisation Effectiveness of immunisation (proportion of cases prevented among those immunised) Results Prevalence reduction due to immunisation, per 1000 women aged 15-44² Range: 0 to 7 Ran	Variables		
Effectiveness of immunisation (proportion of cases prevented among those immunised) Results % prevalence reduction due to immunisation 1 0% Prevalence reduction due to immunisation, per 1000 women aged 15-442 0.000	Coverage of rubella immunisation		Range: 0 to 1
Results % prevalence reduction due to immunisation¹ 0% Prevalence reduction due to immunisation, per 1000 women aged 15-44² 0.000	Proportion of women of reproductive age receiving immunisation		Range: 0 to 1
% prevalence reduction due to immunisation ¹ 0% Prevalence reduction due to immunisation, per 1000 women aged 15-44 ² 0.000	Effectiveness of immunisation (proportion of cases prevented among those immunised)		Range: 0 to 1
Prevalence reduction due to immunisation, per 1000 women aged 15-44 ² 0.000	Results		
	% prevalence reduction due to immunisation ¹	0%	
	Prevalence reduction due to immunisation, per 1000 women aged 15-44 ²	0.000	
Final prevalence of rubella in women aged 15-44 per 1000° 0.000	Final prevalence of rubella in women aged 15-44 per 1000 ³	0.000	

TB = total births (live births + still births)

¹(Coverage of immunisation X Proportion of women receiving immunisation) X Effectiveness of immunisation

²% prevalence reduction due to immunisation X Baseline prevalence of rubella in women

³Baseline prevalence of rubella in women – Prevalence reduction due to immunisation

Preconception care and screening

Effect of preconception screening and treatment on incidence of syphilis

Baseline prevalence of syphilis in pregnancy per 1000 TB		
Variables		
Coverage of preconception screening		Range: 0 to 1
Proportion of diagnosed cases receiving timely treatment		Range: 0 to 1
Effectiveness of treatment (proportion of cases prevented among those treated)		Range: 0 to 1
Results		
% prevalence reduction due to PCCS & treatment ¹	0%	
Prevalence reduction due to PCCS & treatment, per 1000 TB ²	0.000	
Final prevalence of syphilis in pregnancy after PCCS & treatment, per 1000 TB ³	0.000	

PCCS = preconception care and screening TB = total births (live births + still births)

¹(Coverage of screening X Proportion of women receiving treatment) X Effectiveness of treatment

²% prevalence reduction due to PCCS and treatment X Baseline prevalence of syphilis in pregnancy

³Baseline prevalence of syphilis in pregnancy – Prevalence reduction due to PCCS and treatment

Preconception care and screening

Effect of preconception care on congenital disorders caused by teratogens

Baseline prevalence of teratogen-induced congenital disorders per 1000 total births (live + still)		
Variables		
Proportion of women reducing teratogen risk to safe levels prior to pregnancy		Range: 0 to 1
Effectiveness of interventions on the outcome		Range: 0 to 1
Results		
% prevalence reduction due to intervention per 1000 total births¹	0%	
Final prevalence of teratogen-induced congenital disorders per 1000 births ²	0.000	

¹Proportion of women reducing teratogen risk to safe levels prior to pregnancy x Effectiveness if outcome

²Baseline prevalence - (% prevalence reduction due to intervention X Baseline prevalence)